Document Type : Original Research

Authors

1 Department of Pathology, Faculty of Medical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

2 Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

10.30699/ijp.2020.118767.2290

Abstract

Background and Objective: CD137 is a member of the TNF-Receptor family. TNF-alpha antagonists have therapeutic effect in active psoriasis. In this study, the relative frequency of CD137 expression was investigated in the inflammatory cells of psoriasis lesions for the first time.
Methods: The specimens were obtained from pathology department of Al-Zahra hospital from 2007 to 2016, from paraffin-embedded skin biopsies. A number of 64 psoriasis skin lesions specimens and 34 normal skin specimens were rechecked for the diagnosis. Then, the immunohistochemical staining for CD137, CD4, and CD8 was performed.
Results: CD137 expression of dermal inflammatory cells in psoriasis lesion was 11.19±5.5%. Although, in normal skin biopsied, CD137 expression was observed in 1.3±3.03% of the inflammatory cells. (P=0.001). The relative frequency of the CD137 positive inflammatory cells was significantly more in epidermis versus dermis (epidermis: 31.1%±12.8, dermis 11.1%±5.5). There was no remarkable relation between the CD137 expression rate and the CD4: CD8 ratio.
Conclusion: CD137 as a TNF-alpha receptor has a significant role in pathogenesis of the psoriasis lesions. Therefore, CD137 antagonists can be considered as a novel target for the treatment of incurable psoriasis patients.

Keywords

Main Subjects

Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-85. [DOI:10.1038/jid.2012.339] [PMID]

Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13(3):450-6. [DOI:10.1016/S0190-9622(85)70188-0]

Sankar L, Arumugam D, Boj S, Pradeep P. Expression of Angiogenic Factors in Psoriasis Vulgaris. J Clin Diagn Res. 2017;11(3):Ec23-ec7. [DOI:10.7860/JCDR/2017/23039.9525] [PMID] [PMCID]

Sweeney CM, Tobin A-M, Kirby B. Innate immunity in the pathogenesis of psoriasis. Arch Dermatol. 2011;303(10):691-705. [DOI:10.1007/s00403-011-1169-1] [PMID]

Prinz J. The role of T cells in psoriasis. J Eur Acad Dermatol. 2003;17(3):257-70. [DOI:10.1046/j.1468-3083.2003.00720.x] [PMID]

Boehncke W-H. Etiology and pathogenesis of psoriasis. Rheum Dis Clin North Am. 2015;41(4):665-75. [DOI:10.1016/j.rdc.2015.07.013] [PMID]

Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227-55. [DOI:10.1146/annurev-immunol-032713-120225] [PMID] [PMCID]

Al‐Shamkhani A. CD137: costimulator turns suppressor? Immunol. 2004;113(1):23-5. [DOI:10.1111/j.1365-2567.2004.01963.x] [PMID] [PMCID]

Yost J, Gudjonsson JE. The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities. F1000 medicine reports. 2009;1. [DOI:10.3410/M1-30] [PMID] [PMCID]

Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 2005;23:23-68. [DOI:10.1146/annurev.immunol.23.021704.115839] [PMID]

Kienzle G, von Kempis J. CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. Int Immunol. 2000;12(1):73-82. [DOI:10.1093/intimm/12.1.73] [PMID]

Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;9(4):302. [DOI:10.1038/cmi.2012.15] [PMID] [PMCID]

Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G. Targeting tumor necrosis factor α in psoriasis and psoriatic arthritis. Expert Opin Ther Targets. 2008;12(9):1085-96. [DOI:10.1517/14728222.12.9.1085] [PMID]

Aronson PJ. A review of the role of neutrophils in psoriasis and related disorders. Dermatol Online J. 2008;14(7).

Sfikakis P, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis & Rheumatism. 2005;52(8):2513-8. [DOI:10.1002/art.21233] [PMID]

Zhang B, Maris CH, Foell J, Whitmire J, Niu L, Song J, et al. Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J Clin Investig. 2007;117(10):3029-41. [DOI:10.1172/JCI32426] [PMID] [PMCID]

Simon HU. Evidence for a pro-apoptotic function of CD 137 in granulocytes. Swiss Med Wkly. 2001;131(31-32):455-8.

Cabrijan L, Lipozencić J, Batinac T, Peternel S, Pastar Z. The role of CD4 and CD8 lymphocytes and macrophages in psoriasis vulgaris. Acta Dermatovenerol Croat. 2009;17(3):162-5.

Onuma S. Immunohistochemical studies of infiltrating cells in early and chronic lesions of psoriasis. J Dermatol. 1994;21(4):223-32. [DOI:10.1111/j.1346-8138.1994.tb01727.x] [PMID]

Ladizinski B, Lee KC, Wilmer E, Alavi A, Mistry N, Sibbald RG. A review of the clinical variants and the management of psoriasis. Adv Skin Wound Care. 2013;26(6):271-84. [DOI:10.1097/01.ASW.0000429778.10020.67] [PMID]

Eberle FC, Brück J, Holstein J, Hirahara K, Ghoreschi K. Recent advances in understanding psoriasis. F1000Research. 2016;5. [DOI:10.12688/f1000research.7927.1] [PMID] [PMCID]

Ciccarelli F, De Martinis M, Sirufo MM, Ginaldi L. Psoriasis Induced by Anti-Tumor Necrosis Factor Alpha Agents: A Comprehensive Review of the Literature. Acta Dermatovenerol Croat. 2016;24(3):169-74.

Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD open. 2016;2(2):e000239. [DOI:10.1136/rmdopen-2015-000239] [PMID] [PMCID]